Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27810164 | 0.89 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2GAAKMT2ACTSD | |
| SCHEMBL30736569 | 0.87 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2GAAKMT2ACTSD | |
| SCHEMBL954897 | 0.87 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2GAAKMT2ACTSD | |
| SCHEMBL28012073 | 0.82 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2GAACTSDMAPT | |
| SCHEMBL7800011 | 0.82 | CTSD (0.56) | ALDH1A1SMN1; SMN2GAAKMT2ACTSD | |
| SCHEMBL1523174 | 0.80 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2GAAKMT2ACTSD | |
| SCHEMBL18304676 | 0.80 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAAKMT2ACTSD | |
| SCHEMBL29444417 | 0.80 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAAKMT2ACTSD | |
| SCHEMBL1919090 | 0.79 | CYP4F2 (0.63) | ALDH1A1SMN1; SMN2GAAKMT2AMAPT | |
| SCHEMBL11828669 | 0.79 | HRH2 (0.48) | ALDH1A1SMN1; SMN2GAAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399448-B1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-12-01 | — | — | EP | disclosed |
| EP-1399448-A1 | IMIDAZO 1,5-A] PYRIMIDO 5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| US-6686352-B2 | USEFUL AS COGNITIVE ENHANCER OR FOR THERAPY OF COGNITIVE DISORDERS LIKE ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-03-20 | — | — | US | disclosed |
| WO-2002094834-A1 | IMIDAZO [1,5-A] PYRIMIDO [5,4-D] BENZAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055042-A1 | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives | GALR1, GALR2, ADRA1A | ALDH1A1 444/4885SMN1; SMN2 4001/4885GAA 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.